Status:
COMPLETED
The DIOXXACT Trial(Diurnal IOP and OBF Xalatan vs Xalatan And Cosopt Trial)
Lead Sponsor:
Maisonneuve-Rosemont Hospital
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Eye Disease
Eligibility:
All Genders
30-80 years
Phase:
PHASE4
Brief Summary
Diurnal and intervisit fluctuations in IOP are strongly associated with progression of open angle glaucoma and therefore need to be minimized. Control of diurnal fluctuations of IOP with different ocu...
Detailed Description
Twenty patients with open angle glaucoma or ocular hypertension currently on latanoprost immunotherapy will be recruited. A complete routine ophthalmic examination including biomicroscopy, gonioscopy...
Eligibility Criteria
Inclusion
- Subjets with open angle glaucoma or ocular hypertension currently on latanoprost immunotherapy.
- Subjets must have clear media, corrected visual acuity of 6/12 or better,and be able to sit for imaging.
Exclusion
- Subjets with contraindications or known allergies to any of the components of Cosopt.
- Subjets who had undergoing laser or any ocular surgery.
Key Trial Info
Start Date :
May 4 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00957190
Start Date
May 4 2009
End Date
February 1 2012
Last Update
March 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maisonneuve-Rosemont Hospital
Montreal, Quebec, Canada, H1T 2M4